Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE650.503.1 (+0.48 % )
PREV CLOSE (Rs.) 647.40
OPEN PRICE (Rs.) 643.00
BID PRICE (QTY) 650.60 (167 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 62144
TODAY'S LOW / HIGH (Rs.)643.00 655.00
52 WK LOW / HIGH (Rs.)525.65 718.35
NSE650.70 3 (+0.46 % )
PREV CLOSE(Rs.) 647.70
OPEN PRICE (Rs.) 648.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 650.70 (77 )
VOLUME 937081
TODAY'S LOW / HIGH(Rs.) 645.00 655.00
52 WK LOW / HIGH (Rs.)525.25 718

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 404.60
Dividend Yield(%) 0.15
TTM EPS (Rs.) 7.75
P/E Ratio 83.92
Book Value (Rs.) 117.12
Face Value (Rs.) 5
MCap (Rs. in Mn) 390300.00
Price/Earning (TTM) 64.78
Price/Sales (TTM) 14.89
Price/Book (MRQ) 5.55
PAT Margin (%) 9.83
ROCE (%) 4.53
Incorporation Year : 1978

Management Info :

Kiran Mazumdar-Shaw - Chairman Kiran Mazumdar-Shaw - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 91-80-2808-2808

Website : www.biocon.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
19Dec12-19-2018$Biocon, Mylan’s joint product Ogivri gets approval in EU Biocon, Mylan’s joint prod

Biocon and Mylan’s jointly developed product -- Ogivri, a biosimilar Trastuzumab, has been approved in the European Union (EU). The European Commission has granted Marketing Authorization for Ogivri to the company’s partner Mylan.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) previously issued a positive opinion recommending approval of Ogivri as a biosimilar to Roche's Herceptin (Trastuzumab) on October 18, 2018.

Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon and Mylan’s jointly developed product -- Ogivri, a bio..
18Dec12-18-2018$Biocon trades higher on the bourses Biocon trades higher on the

Biocon is currently trading at Rs. 638.80, up by 5.50 points or 0.87% from its previous closing of Rs. 633.30 on the BSE.

The scrip opened at Rs. 632.00 and has touched a high and low of Rs. 640.50 and Rs. 631.35 respectively. So far 58412 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 718.35 on 26-Sep-2018 and a 52 week low of Rs. 508.00 on 18-Dec-2017.

Last one week high and low of the scrip stood at Rs. 658.45 and Rs. 628.90 respectively. The current market cap of the company is Rs. 38244.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.94% and 17.38% respectively.

US Food and Drug Administration (USFDA) has conducted a GMP inspection at Biocon's API manufacturing facility at Telangana from December 12 to 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects company's strong commitment to quality and cGMP compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide

Biocon is currently trading at Rs. 638.80, up by 5.50 points or..
17Dec12-17-2018$USFDA concludes inspection at Biocon's API manufacturing facility in Telangana USFDA concludes inspection a

US Food and Drug Administration (USFDA) has conducted a GMP inspection at Biocon's API manufacturing facility at Telangana from December 12 to 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects company's strong commitment to quality and cGMP compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

US Food and Drug Administration (USFDA) has conducted a GMP ins..
17Dec12-17-2018$Biocon informs about company updates Biocon informs about company

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, Biocon has informed about the company statement that the U.S. FDA conducted a GMP inspection of our APIs manufacturing facility at Telangana from December 12- December 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects the company's strong commitment to quality and cGMP compliance.

The above information is a part of company's filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, B..
05Dec12-05-2018$Biocon rises on the bourses Biocon rises on the bourses

Biocon is currently trading at Rs. 627.25, up by 3.65 points or 0.59% from its previous closing of Rs. 623.60 on the BSE.

The scrip opened at Rs. 621.55 and has touched a high and low of Rs. 629.10 and Rs. 619.10 respectively. So far 33538 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 718.35 on 26-Sep-2018 and a 52 week low of Rs. 503.30 on 06-Dec-2017.

Last one week high and low of the scrip stood at Rs. 634.00 and Rs. 590.60 respectively. The current market cap of the company is Rs. 37491.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.94% and 17.38% respectively.

Biocon’s CSR arm -- Biocon Foundation and Syngene International have dedicated the newly revived Hebbagodi Lake in Anekal taluk in Karnataka to the community. Besides, the bio-rejuvenated lake, a Children's Park and a safe drinking water facility using Reverse Osmosis (RO) technology were also opened for the public.

As a part of its efforts to ensure environmental sustainability, Biocon Foundation, with approvals from the Karnataka Lake Conservation and Development Authority (KLCDA) and other government authorities, has brought back to life the dying 35-acre Hebbagodi Lake, leading to a significant improvement in the water quality and the return of flora and fauna.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 627.25, up by 3.65 points or..
Financials More
Rs. in Millions
QTR Sep 18 ANNUAL 18
Net Profit11982385
Gross Profit 1409 3058
Operating Profit 14764429
Net Sales 708924255
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 6366.20 (2.22%)
M.Cap ( in Cr)
14661.75
Eris Lifesciences (BSE)
 709.15 (9.96%)
M.Cap ( in Cr)
9752.06
Torrent Pharma (BSE)
 1945.25 (2.84%)
M.Cap ( in Cr)
32918.05
Dr. Reddys Lab (BSE)
 2621.85 (1.15%)
M.Cap ( in Cr)
43538.67
Piramal Enterprises (BSE)
 2367.35 (0.99%)
M.Cap ( in Cr)
43420.10
Shareholding Pattern More
PROMOTERS 61.48 %
MUTUAL FUNDS/UTI 2.96 %
NON-INSTITUTION 16.44 %
FI/BANKS/INSURANCE 1.16 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested